Riskpilot← Back to searchSign inGet full accessApoteksgruppen i Bromma Nr 2 AB
ABActiveOrg 5569578155Tranebergsplan 1Retail sale of pharmaceutical products · NACE 4773Est. 20145-9 employees
Revenue 2024
SEK 30,7M
+5% vs 2023
EBITDA margin
6.0%
+37% vs 2023
Equity ratio
43.0%
Financial strength
Net profit 2024
SEK 1,1M
+2% vs 2023
| Revenue | SEK 30,7M | +5% |
| EBITDA | SEK 1,8M | +37% |
| Net profit | SEK 1,1M | +2% |
| Total assets | SEK 8,1M | -1% |
| Equity | SEK 3,5M | -8% |
| Employees | — | — |
Legal name
Apoteksgruppen i Bromma Nr 2 AB
Org number
5569578155
Legal form
Aktiebolag
NACE code
4773 · Retail sale of pharmaceutical products
Founded
9 januari 2014
Share capital
SEK 100 000
Employees
5-9
VAT registered
Yes
Audit selected
No
Last report
2024-12-31
Financial year
January – December
Signatory rights
Firman tecknas av styrelsen
Company purpose
Bolaget har till föremål för sin verksamhet att bedriva handel med receptbelagda apoteksvaror, receptfria apoteksvaror och handelsvaror som lämpar sig för försäljning och distribution till konsumenter genom apotek samt därmed förenlig verksamhet.
Address
Tranebergsplan 1
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| Revenue | 26 293 | 26 874 | 28 444 | 29 414 | 30 746 |
| Staff expenses | — | — | −2 401 | −2 485 | −2 471 |
| EBITDA | 1 415 | 1 277 | 1 311 | 1 354 | 1 849 |
| Depreciation & amort. | −456 | −312 | −249 | −249 | −154 |
| EBIT | 959 | 965 | 1 062 | 1 104 | 1 696 |
| Net financials | −85 | −57 | −29 | −5 | −15 |
| Profit before tax | 175 | 909 | 813 | 1 348 | 1 377 |
| Tax | −40 | −189 | −168 | −282 | −289 |
| Net profit | 135 | 720 | 644 | 1 066 | 1 088 |
| Item | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| Total assets | 6 917 | 7 728 | 7 790 | 8 245 | 8 147 |
| Equity | 1 387 | 2 107 | 2 751 | 3 817 | 3 506 |
| Long-term debt | 1 246 | 910 | 490 | 0 | — |
| Short-term debt | 3 584 | 4 011 | 3 629 | 3 757 | 3 667 |
| Total debt | 4 830 | 4 921 | 4 119 | 3 757 | 3 667 |
EBITDA margin
6.0%
This company
15.8%
Market median
-62% vs market
20202024
Equity ratio
43.0%
This company
38.2%
Market median
+13% vs market
20202024
Return on equity
31.0%
This company
18.4%
Market median
+68% vs market
20202024
Net profit margin
3.5%
This company
8.1%
Market median
-57% vs market
20202024
Asset turnover
3.77×
This company
1.12×
Market median
+237% vs market
20202024
Debt / equity
1.32×
This company
0.62×
Market median
-113% vs market
20202024
- Annual report 2024Filed via Bolagsverket / SCB · Period 2024-01-01 – 2024-12-31
- Annual report 2023Filed via Bolagsverket / SCB · Period 2023-01-01 – 2023-12-31
- Annual report 2022Filed via Bolagsverket / SCB · Period 2022-01-01 – 2022-12-31
- Annual report 2021Filed via Bolagsverket / SCB · Period 2021-01-01 – 2021-12-31
- Annual report 2020Filed via Bolagsverket / SCB · Period 2020-01-01 – 2020-12-31
| Name | Role | Member since |
|---|---|---|
| Current (2) | ||
ME Chief Auditor | Chief Auditor | 2022 |
JD Chief Executive Officer | Chief Executive Officer | 2022 |
| Name | Role | Member since |
|---|---|---|
| Current (1) | ||
| Deputy Board Member | 2022 | |
| Former (1) | ||
| Chairman | 2022 – 2024 | |
| Shareholder | Type | Ownership | Votes | Since |
|---|---|---|---|---|
| Company | 99% | 99% | 2023 |
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
Apotekia AB
Apoteksgruppen i Bromma Nr 2 AB Board members of Apoteksgruppen i Bromma Nr 2 AB also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Malin Elisabeth Terneblad | Chief Auditor | 0 companies |
| Johan Daniel Bergheden | Chief Executive Officer | 0 companies |
| Elna Margareta Bergheden | Deputy Board Member | 0 companies |
| Karl Andreas Olofsson | Chairman | 0 companies |